title: Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?
authors.forename: S
authors.initials: S
authors.lastname: Postel-Vinay
authors.forename: M
authors.initials: M
authors.lastname: Schlumberger
authors.forename: J-C
authors.initials: JC
authors.lastname: Soria
mesh_terms: D000813:Anilides / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D002116:Calcitonin / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D018278:Carcinoma, Neuroendocrine; D018450:Disease Progression; D006801:Humans; D010880:Piperidines / Q000627:therapeutic use; D051096:Proto-Oncogene Proteins c-ret / Q000037:antagonists & inhibitors* / Q000235:genetics; D011725:Pyridines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000235:genetics
chemical_list: D000813:Anilides; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D010880:Piperidines; D011725:Pyridines; D011799:Quinazolines; C558660:cabozantinib; D002116:Calcitonin; D051096:Proto-Oncogene Proteins c-ret; C099282:RET protein, human; C452423:vandetanib